What a GI-MAP report can and cannot answer
DNA from a disease-causing microbe may need a standard infection test. Calprotectin, pancreatic elastase, and hidden blood each need their own follow-up. Flags for ordinary gut microbes or “dysbiosis” are less clear. Treating every colored line can lead to unneeded drugs, strict diets, supplements, and repeat tests.
Pathogen DNA
Confirm a positive DNA finding with the appropriate standard test before treatment
A microbial DNA signal can fit infection, colonization, background, or a false result. Symptoms, exposure, and a standard targeted pathway decide what it means.
Stool markers
Some report lines need separate clinical evaluation
Read calprotectin, pancreatic elastase, and hidden blood as separate stool tests. An abnormal result isn't proof a microbiome imbalance caused it.
Microbiome
Dysbiosis is not a settled diagnosis
Current consensus does not support one healthy species-abundance profile or routine treatment advice from commercial microbiome reports.
Brain fog
The report cannot name the cause
Digestive illness, dehydration, bleeding, poor absorption, medicines, sleep disruption, and restricted eating can overlap with brain fog. GI-MAP does not show which one is responsible.
A named pathogen, a high inflammation marker, a low digestive marker, and a low ordinary gut microbe are different findings. Keep each one with its test method and follow-up.
Save this test
Save this test guide
Save a link to this guide in My Fog so you can open it again. Keep your lab report separately.
Use the record to support a clinician-led infection, inflammation, digestion, bleeding, celiac, medication, or bowel-symptom review. Do not use it as proof that gut bacteria caused brain fog.
What can change how a GI-MAP result is read?
GI-MAP has no proven normal microbiome range by age or sex. Age, pregnancy, immune health, medicines, travel, bowel changes, and the reason for testing matter more.
Babies and young children
Do not use adult microbiome ranges for a baby or child. Diarrhea can dry out infants quickly. Contact a clinician promptly for a child younger than 12 months, a premature child, or a child who cannot drink enough. Also call for dehydration, blood, black stool, severe pain, frequent vomiting, or marked sleepiness.
Children and teenagers
Use pediatric symptoms, growth, hydration, travel, exposure, medicines, immune status, and a pediatric testing pathway. A private stool panel should not start antimicrobial or restrictive-diet treatment without a clinician who can check nutrition and development.
Adult women and men
The panel has no separate dysbiosis cutoff for males and females. Record age, sex, bowel speed, food, alcohol, smoking, body size, medicines, and health history. The 2025 consensus uses these as context, not separate healthy targets.
Pregnancy and postpartum
Pregnancy raises the need to act early on dehydration, fever, repeated vomiting, blood, severe pain, or inability to keep fluids down. Do not start herbs, antimicrobials, supplements, or a restrictive diet from a microbiome flag without pregnancy-specific review.
Older adults and people with weaker immunity
People over 65, those taking antibiotics, and those with weakened immune systems have a higher risk of complications from diarrhea. A broad report should not delay standard stool testing, hydration assessment, medication review, or urgent care when symptoms are significant.
How to collect and what to record
Confirm the exact order before collecting. GI-MAP, GI-MAP plus Zonulin, a pathogen-only option, an H. pylori profile, and separately ordered markers do not produce the same report. Ask what result would actually change care.
Keep your usual diet. Keep taking medicine and supplements unless the ordering clinician or current kit tells you to stop. Write down recent antibiotics, acid-reducing medicine, laxatives, probiotics, supplements, and other treatment.
Read the kit before opening the vial. The US instructions say to wear gloves and pass stool into the tray. Urinate first when possible so urine does not mix with the sample. Collect stool from at least four areas.
Keep the pink preservative in the vial. Fill above the red line without overfilling, close the cap tightly, mix the stool and fluid, and shake for 30 seconds. Label the vial with the required name, date of birth, and collection date.
Ship on the collection day when possible. The sample must arrive within eight days. If you cannot ship that day, refrigerate it and ship as soon as possible, preferably within three days. Follow your kit if its rules differ.
Write down stool form and frequency. Also note blood or black stool, pain, fever, vomiting, and weight change. Add travel, unsafe food or water, sick contacts, antibiotics, hospital care, weak immunity, pregnancy, and the reason for testing.
Write down what the sample is meant to check
Write whether the concern is acute diarrhea, persistent diarrhea after travel, H. pylori, possible gut inflammation, poor digestion, or a private microbiome review. One panel cannot make those questions interchangeable.
Collect the stool, not a blood sample
Use the supplied tray and vial. Keep urine and toilet water out. Sample at least four areas, keep the preservative, fill to the line, close, shake, label, and ship as instructed.
Split the report into sections
Separate named pathogens and H. pylori from inflammatory or digestive markers, then put commensal, opportunistic, dysbiosis, immune, and resistance-gene flags in a third group.
Confirm what would trigger treatment
Before antibiotics, antiparasitics, antifungals, eradication therapy, supplements, or restriction, ask whether the finding fits the symptoms and needs a standard targeted test.
Keep the unresolved symptom visible
A long report can distract from bleeding, dehydration, weight loss, fever, severe pain, persistent diarrhea, anemia, or medication effects that require a different workup.
How to read a GI-MAP result
Start with the reason for testing. Then sort each line into one of four groups: no useful match, unclear microbiome flags, pathogen or H. pylori DNA, or a stool test like calprotectin, elastase, or hidden blood.
No actionable match
No named pathogen or marker-specific finding that fits the clinical question
No matching finding was reported. This doesn't prove that the gut is healthy. If symptoms continue, ask whether a standard test is still needed.
Uncertain microbiome or low-level flags
Commensal, opportunistic, immune, dysbiosis, resistance-gene, or low-level DNA flags without a matching clinical syndrome
It may not be clear what these flags mean for your health. Save the exact organism, amount, method, symptoms, medicines, and report wording. A flag alone doesn't prove an infection or show that you need supplements.
Named pathogen or H. pylori DNA
Named pathogen or H. pylori DNA detected in a person with compatible symptoms or exposure
Ask whether a standard test should confirm the result before treatment. This may be a toxin, antigen, breath, culture, or public-health test. Urgent symptoms or an outbreak can change what happens next.
Marker-specific abnormality
High calprotectin, low pancreatic elastase, occult blood, or another marker-specific abnormality
Read this marker separately from the microbiome flags. The next step depends on the marker and symptoms. It may include another stool test, blood work, imaging, a scope, or a gut specialist.
GI-MAP accuracy cannot be summarized by one marketing claim
The panel uses many targets and methods. One independent 2020 lab study used 16 spiked samples and seven negative controls. It found 80% sensitivity and 26% specificity for the GI-MAP pathogen test it studied. The study was small and cannot tell us how every current result performs. Still, confirm any result that could change treatment.
See research details
Keep collection instructions, the direct performance study, infectious-disease guidance, microbiome consensus, commercial-service variability, and symptom-led testing as separate evidence.
Save the exact panel version, order, laboratory, report date, units, detection wording, and add-ons. Do not assume a threshold from this report transfers to an FDA-cleared infectious-diarrhea panel or another laboratory.
A result that would trigger antimicrobial treatment deserves symptom fit and, when available, confirmation through the current standard pathway.
Read the organism beside diarrhea type, timing, travel, food and water exposure, fever, blood, immune status, antibiotics, and outbreak context. A flag without the matching illness may need confirming, not treating.
Read commensal, diversity, dysbiosis, and opportunistic flags as uncertain. They aren't a diagnosis, diet rule, or supplement list. Changes in care belong with a qualified clinician and the symptom-specific evidence.
Do not compare a result with another company's healthy range or interpret a change between methods as a biological recovery or decline.
Use the duration, alarm features, travel, medicines, and the decision the test must change. A focused standard test can be more useful than treating every line in a broad panel.
What you can do before acting on the report
While you wait for a review, drink enough fluids, keep a short symptom record, and avoid buying treatment for every flag.
Protect fluids and ordinary food
With loose stool, replace fluids and electrolytes and return to normal tolerated food as appetite returns. Keep infants on breast milk or formula as advised. Do not use a prolonged fast, cleanse, or severe elimination diet to improve a report.
Make one short bowel and exposure record
For one to two weeks, note stool form, frequency, pain, urgency, blood, fever, vomiting, and weight change. Add meals, travel, water, sick contacts, medicines, antibiotics, acid reducers, laxatives, probiotics, and when brain fog worsened. Stop when the timing is clear.
Review the report line by line
Mark each line as pathogen DNA, H. pylori, inflammation, digestion, blood, immune marker, commensal, opportunistic organism, or add-on. Beside it, write the standard confirmation test and what treatment decision would change.
Pause the treatment shopping list
Do not buy multiple probiotics, binders, enzymes, biofilm products, antifungals, or herbal antimicrobials to correct every colored flag. Ask which finding has a validated clinical meaning and whether an ordinary diet or targeted diagnosis makes the expensive plan unnecessary.
Use a standard test for the condition being checked
For H. pylori, current ACG follow-up uses fecal antigen, urea breath testing, or gastric biopsy at the correct time after treatment. For chronic watery diarrhea, a focused pathway may include calprotectin, Giardia, celiac testing, or bile-acid evaluation. The exact choice comes from the symptom and history.
Get prompt medical care for dehydration, black or bloody stool, pus, severe belly or rectal pain, or frequent vomiting. High fever or six or more loose stools a day also needs prompt care. Call for confusion, marked sleepiness, or diarrhea during pregnancy, after antibiotics, after age 65, or with weak immunity.
What to save from a GI-MAP report
Keep these together
- Exact GI-MAP order, panel version, laboratory, report date, add-ons, collection date, shipping date, refrigeration, sample problems, and any repeat
- Stool form and frequency, diarrhea duration, constipation, pain, blood or black stool, fever, vomiting, weight change, appetite, hydration, travel, food or water exposure, and sick contacts
- Antibiotics, acid-reducing medicine, laxatives, probiotics, supplements, immune suppression, recent hospital care, pregnancy, age, and the reason for testing
- Named pathogen and H. pylori DNA lines, quantities and units, virulence or resistance genes, detection wording, and any standard confirmation result
- Calprotectin, pancreatic elastase, hidden blood, immune results, commensal and opportunistic flags, clinician interpretation, treatment decision, and follow-up plan
Question for the visit
“Which GI-MAP finding has validated clinical meaning for my symptoms, which standard targeted test could confirm it, and what result would actually change treatment?”
Sources for GI-MAP Stool DNA Test
Exact collection, labeling, preservative, shaking, shipping, refrigeration, and medicine safety instructions.
Manufacturer description of qPCR targets, report groupings, genome-equivalent units, markers, and laboratory-developed-assay statement.
Symptom and exposure selection, multiplex nucleic-acid limits, viable-organism caution, and public-health context.
Current symptom-led test selection, specimen handling, and adult and pediatric laboratory context.
Molecular-test colonization, overdiagnosis, pretest-probability, toxin, and multistep-testing cautions.
Targeted adult calprotectin or lactoferrin, Giardia, celiac, and bile-acid diarrhea pathway.
Warning against routine enteric-pathogen testing for every person with IBS without high pretest probability.
Current eradication confirmation by fecal antigen, urea breath testing, or gastric biopsy with medication and timing conditions.
Hydration, normal diet return, child feeding, duration, and symptom-led diagnosis.
Adult, child, pregnancy, older-adult, immune, antibiotic, dehydration, bleeding, pain, and vomiting safety context.
Seven-service standardized-material comparison, within- and between-provider discrepancies, and analytical-validity need.
Independent GI-MAP challenge study with 16 spiked samples, seven controls, 80 percent sensitivity, 26 percent specificity, and study limits.
International 69-expert, 18-country consensus on limited routine microbiome-test utility, reference ranges, pretest context, and treatment advice.
One-sample comparison of six commercial microbiome services reviewed by 21 experts, with substantial cross-service disagreement and clear limits.
See each claim's sources
procedure
Current GI-MAP instructions use a preserved stool vial, sampling from at least four areas, a marked fill line, 30 seconds of shaking, prompt shipping, and refrigeration when same-day shipping is not possible.limitation
A small independent spiked-sample study of the tested GI-MAP version reported 80 percent sensitivity and 26 percent specificity and supports confirmation before treatment-changing interpretation.limitation
Stool nucleic-acid detection does not by itself prove viable organisms or active disease and must be read with symptoms and pretest probability.limitation
Current international consensus finds insufficient evidence for routine clinical microbiome testing and does not support strict healthy species-abundance ranges or provider-issued treatment advice from a report.limitation
Commercial microbiome services can produce substantially different profiles and recommendations from the same stool sample, although the cited comparison was not GI-MAP-specific.procedure
Symptom-led diarrhea and H. pylori pathways use targeted tests and confirmation rather than treating every line in a broad stool report.